“…One challenge to advancing the field lies in the modification itself, which is challenging to detect and resists genetic/pharmacological manipulation. There have been a number of recent advances in methodologies for detecting O-GlcNAc modified proteins (28, 75, 76, 81, 123, 141, 151, 158, 159, 163-166, 170, 171, 192, 193), mapping the sites of addition of OGlcNAc (11,14,81,141,151,170), probing the dynamics of O-GlcNAcylation (12,13,77,165,168,194), and genetic models in which O-GlcNAc levels can be manipulated (5,49,73,131,146,172). Together, this suite of technologies should allow researchers to answer some of the key remaining questions: 1) How is the specificity of OGT and O-GlcNAcase regulated, and how is this altered during aging or in disease models?…”